AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model

“This first landmark economic model examines the continuum of definitive care in burns and can bring value to the burn community by estimating the likely economic impact of new treatments for burns,” said Pinar Bilir, IQVIA.

ARANZ Medical’s Pedigree in Clinical Trials Makes Silhouette(R) the Obvious Choice for New Research

April 24, 2018 ARANZ Medical reports their Silhouette skin imaging and measuring solutions have powered more than 100 clinical trials since 2007, and are proving to be a reliable choice for companies undertaking multi-center clinical trials. The company reports...

RECELL Pivotal Trial in Third-Degree Burns Meets Co-Primary Endpoints and Shows Statistically Significant Reduction in Donor Skin Requirements

ReCell pivotal, controlled clinical trial in the treatment of deep full-thickness (third-degree) burns with the RECELL® Autologous Cell Harvesting Device achieved its co-primary endpoints, demonstrating a statistically significant reduction in donor skin requirements versus standard of care while achieving comparable definitive wound closure.

RECELL Study in Facial Burns Shows Excellent Cosmetic Outcomes

4/13/18: Two presentations at the American Burn Association Meeting highlight potential of RECELL to improve patient care in difficult-to-treat burns.

RECELL Data Demonstrating Statistically Significant Reduction in Donor Skin Requirements and Pain, Increased Patient Satisfaction and Improved Donor Scar Outcomes for Second-Degree Burn Patients

RECELL Device presentations include data from pivotal trial and health economic results showing 44 percent reduction in total treatment costs compared to standard of care.

Wound Management Technologies Changes Name to WNDM Medical

4/3/18: New name better reflects breadth of products and long-term vision for growth.

Avita Medical Announces Submission of U.S. FDA Premarket Approval Application for the ReCell Device for Treatment of Burn Injuries

September 28, 2018 Avita Medical announced today that it has submitted to the Food & Drug Administration (FDA) a Pre-Market Approval (PMA) application for its ReCell Autologous Cell Harvesting Device for treatment of burn injuries. The company reports that...

LimbFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study

LimbFlow reports this clinical trial is the initial step towards a U.S. approval pathway for the LimFlow System.